Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

被引：54
|
作者：
Boeckx, Carolien [1 ]
de Beeck, Ken Op [1 ,2 ,3 ]
Wouters, An [1 ]
Deschoolmeester, Vanessa [1 ]
Limame, Ridha [1 ]
Zwaenepoel, Karen [4 ]
Specenier, Pol [1 ,5 ]
Pauwels, Patrick [1 ,4 ]
Vermorken, Jan B. [1 ,5 ]
Peeters, Marc [1 ,5 ]
Van Camp, Guy [2 ,3 ]
Baay, Marc [1 ]
Lardon, Filip [1 ]
机构：
[1] Univ Antwerp, CORE Antwerp, Lab Canc Res & Clin Oncol, Antwerp, Belgium
[2] Univ Antwerp, Ctr Med Genet, Dept Biomed Sci, Antwerp, Belgium
[3] Univ Antwerp Hosp, Antwerp, Belgium
[4] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium
[5] Univ Antwerp Hosp, Dept Med Oncol, Antwerp, Belgium
来源：
CANCER LETTERS | 2014年 / 354卷 / 02期
关键词：
Head and neck squamous cell carcinoma; Anti-EGFR therapy; Cetuximab resistance; Dual-specificity phosphatase 5 and 6; Aurora kinase B; Nano Pro 1000; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; APIGENIN INDUCES APOPTOSIS; NECK-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; MESENCHYMAL TRANSITION; AURORA KINASES; MONOCLONAL-ANTIBODY;
D O I：
10.1016/j.canlet.2014.08.039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Our microarray results suggest that "resistant" cells still exhibit RAS-MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of DUSP5 and DUSP6, negative regulators of ERK1/2, and increased expression of AURKB, a key regulator of mitosis. Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCc. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：365 / 377
页数：13
相关论文
共 50 条
  • [1] Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP6
    Boeckx, Carolien
    Deschoolmeester, Vanessa
    Wouters, An
    de Beeckx, Ken Op
    Pauwels, Patrick
    Vanderveken, Olivier
    van Camp, Guy
    Vanden Berghe, Wim
    Specenier, Pol
    Vermorken, Jan B.
    Peeters, Marc
    Baay, Marc
    Lardon, Filip
    CANCER RESEARCH, 2013, 73 (08)
  • [2] Overcoming intrinsic and acquired cetuximab resistance: an in vitro study on the potential of afatinib in HNSCC cell lines
    De Pauw, Ines
    Wouters, An
    Van den Bossche, Jolien
    Deschoolmeester, Vanessa
    Pauwels, Patrick
    Vermorken, Jan B.
    Peeters, Marc
    Lardon, Filip
    CANCER RESEARCH, 2017, 77
  • [3] Mechanisms underlying resistance to cetuximab in the HNSCC cell line: Role of AKT inhibition in bypassing this resistance
    Rebucci, Magali
    Peixoto, Paul
    Dewitte, Amelie
    Wattez, Nicole
    De Nuncques, Marie-Adeline
    Rezvoy, Nicolas
    Vautravers-Dewas, Claire
    Buisine, Marie-Pierre
    Guerin, Eric
    Peyrat, Jean-Phlippe
    Lartigau, Eric
    Lansiaux, Amelie
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (01) : 189 - 200
  • [4] Targeting BRD4 overcomes cetuximab resistance in HNSCC
    Brand, Toni
    Zeng, Yan
    Leonard, Brandon
    Keefe, Rachel O'
    Li, Hua
    Johnson, Daniel
    Grandis, Jennifer
    Bhola, Neil E.
    CANCER RESEARCH, 2017, 77
  • [5] Biomarkers of resistance to cetuximab in head and neck squamous cell carcinoma (HNSCC).
    Surikova, Ekaterina I.
    Kit, Oleg I.
    Neskubina, Irina V.
    Frantsiyants, Elena M.
    Vladimirova, Liubov Yu
    Lyanova, Aza A.
    Engibaryan, Marina A.
    Shalashnaya, Elena V.
    Aedinova, Irina V.
    Ulianova, Yulia V.
    Volkova, Viktoriya L.
    Pustovaya, Irina Viktorovna
    Ezhova, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] PTEN and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC).
    Da Costa, Alexandre Andre B. A.
    Costa, Felipe D'Almeida
    De Oliveira, Andrea Cruz Ferraz
    Stecca, Carlos
    Oliveira, Audrey
    Alves, Ana Caroline Fonseca
    Camandaroba, Marcos Pedro Guedes
    Araujo, Daniel Vilarim
    Machado, Larissa
    De Lima, Vladmir Claudio Cordeiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Transcriptional and epigenetic regulation of resistance markers in cetuximab sensitive HNSCC cells
    Kagohara, Luciane T.
    Zamuner, Fernando
    Considine, Michael
    Stein-O'Brien, Genevieve
    Sherman, Thomas
    Gaykalova, Daria A.
    Fertig, Elana J.
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
    O'Keefe, Rachel A.
    Bhola, Neil E.
    Lee, David S.
    Johnson, Daniel E.
    Grandis, Jennifer R.
    PLOS ONE, 2020, 15 (01):
  • [9] Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol
    Pearson, Hannah E.
    Iida, Mari
    Orbuch, Rachel A.
    McDaniel, Nellie K.
    Nickel, Kwangok P.
    Kimple, Randall J.
    Arbiser, Jack L.
    Wheeler, Deric L.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 204 - 214
  • [10] Resistance to cetuximab -: implication of PTEN expression in the cellular sensitivity to cetuximab (Erbitux®) of Head and Neck Squamous Cell Carcinoma (HNSCC)
    Mriouah, J.
    Chartier, C.
    Boura, C.
    Fifre, A.
    Fries, I.
    Ramacci, C.
    Merlin, J. L.
    Faivre, B. M. A.
    EJC SUPPLEMENTS, 2008, 6 (09): : 112 - 112
12345